ELEVANCE HEALTH ($ELV) posted quarterly earnings results for Q4 2025 on Wednesday, January 28th. The company reported earnings of $3.33 per share, beating estimates of $3.13 by $0.20. The company also reported revenue of $49,311,000,000, missing estimates of $50,314,506,864 by $-1,003,506,864.
You can see Quiver Quantitative's $ELV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELEVANCE HEALTH Insider Trading Activity
ELEVANCE HEALTH insiders have traded $ELV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:
- SUSAN D. DEVORE purchased 1,200 shares for an estimated $374,580
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ELEVANCE HEALTH Hedge Fund Activity
We have seen 686 institutional investors add shares of ELEVANCE HEALTH stock to their portfolio, and 831 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 3,533,312 shares (-54.5%) from their portfolio in Q3 2025, for an estimated $1,141,683,773
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,246,294 shares (-27.8%) from their portfolio in Q3 2025, for an estimated $725,822,517
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,792,797 shares (+60.2%) to their portfolio in Q3 2025, for an estimated $579,288,566
- ORBIS ALLAN GRAY LTD removed 1,547,732 shares (-54.2%) from their portfolio in Q3 2025, for an estimated $500,103,163
- GQG PARTNERS LLC removed 1,463,610 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $472,921,663
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 1,242,850 shares (-89.4%) from their portfolio in Q3 2025, for an estimated $401,589,692
- AMERIPRISE FINANCIAL INC removed 1,150,939 shares (-61.4%) from their portfolio in Q3 2025, for an estimated $371,891,409
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELEVANCE HEALTH Government Contracts
We have seen $298,045,337 of award payments to $ELV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK): $133,168,083
- J6 A/B MAC SERVICES: $79,005,474
- NEXT GENERATION DESKTOP IGF::OT::IGF: $64,075,990
- SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE OF SPA...: $11,890,083
- THE CONTRACTOR SHALL PROVIDE SUPPLIES AND/OR SERVICES TO PROVIDE A SINGLE FRONT-END SOLUTION FOR THE SUBMIS...: $4,213,107
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ELEVANCE HEALTH Congressional Stock Trading
Members of Congress have traded $ELV stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/13.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 08/05.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ELEVANCE HEALTH Analyst Ratings
Wall Street analysts have issued reports on $ELV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 01/07/2026
- TD Cowen issued a "Buy" rating on 11/26/2025
- Mizuho issued a "Outperform" rating on 11/04/2025
- JP Morgan issued a "Overweight" rating on 10/28/2025
- Barclays issued a "Overweight" rating on 10/22/2025
- Guggenheim issued a "Buy" rating on 10/08/2025
- UBS issued a "Buy" rating on 09/05/2025
To track analyst ratings and price targets for ELEVANCE HEALTH, check out Quiver Quantitative's $ELV forecast page.
ELEVANCE HEALTH Price Targets
Multiple analysts have issued price targets for $ELV recently. We have seen 12 analysts offer price targets for $ELV in the last 6 months, with a median target of $400.0.
Here are some recent targets:
- Jason Cassorla from Guggenheim set a target price of $414.0 on 01/22/2026
- Justin Lake from Wolfe Research set a target price of $425.0 on 01/08/2026
- Stephen Baxter from Wells Fargo set a target price of $424.0 on 01/07/2026
- Andrew Mok from Barclays set a target price of $404.0 on 01/05/2026
- George Hill from Deutsche Bank set a target price of $320.0 on 12/19/2025
- Erin Wright from Morgan Stanley set a target price of $352.0 on 12/18/2025
- Ryan Langston from TD Cowen set a target price of $400.0 on 11/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
